Bispecific antibodies are engineered immune proteins designed to bind two different targets at once. Unlike conventional antibodies, which lock onto a single molecule, bispecific antibodies can grab one target with one arm and a completely different target with the other. This dual-binding ability opens up strategies that weren’t possible before, most notably pulling immune cells into direct contact with cancer cells to destroy them. As of mid-2025, more than 180 bispecific antibodies are being tested in clinical trials, with several already approved for use in blood cancers and solid tumors.
How They Differ From Standard Antibodies
Your immune system naturally produces antibodies that each recognize one specific target. These Y-shaped proteins have two identical arms, and both arms bind the same molecule. Pharmaceutical companies have spent decades developing monoclonal antibodies (lab-made versions of these single-target proteins) into some of the most successful drugs in modern medicine.
Bispecific antibodies break that one-target rule. Engineers modify the two arms so each one binds a different molecule. One arm might latch onto a protein found on a tumor cell while the other grabs a protein on an immune cell. The result is a molecular bridge that physically links two cells together, forcing an interaction that wouldn’t happen on its own. This bridging concept is the core innovation, and it’s what makes bispecific antibodies fundamentally different from simply combining two separate drugs.
The Two Main Structural Designs
Bispecific antibodies come in dozens of engineered formats, but they fall into two broad categories. The first group, called IgG-like bispecifics, looks similar to a natural antibody. They have a full Y-shaped structure with two heavy protein chains and two light chains, plus a “tail” region that interacts with the immune system. Their larger size gives them a longer lifespan in the bloodstream, which means less frequent dosing.
The second group strips away the tail entirely, leaving only the binding portions connected by short protein linkers. These non-IgG-like formats are smaller and more flexible. The best-known example is the BiTE (bispecific T-cell engager) format, which links two minimal binding fragments back to back. That compact size comes with a tradeoff: BiTE molecules are cleared from the body quickly, with a half-life of roughly 1.25 hours. That’s why they’re typically delivered as a continuous intravenous infusion over weeks rather than as a single injection.
How T-Cell Engaging Bispecifics Kill Cancer
The most clinically advanced use of bispecific antibodies is redirecting the body’s own T cells (the immune system’s primary killers) to attack cancer. Here’s how it works: one arm of the antibody binds CD3, a signaling protein found on virtually all T cells, while the other arm binds a protein on the surface of the tumor cell. When both arms are engaged, the antibody physically pulls the T cell and cancer cell together.
What happens next closely mimics a natural immune attack. The T cell forms what’s called an immunological synapse, a tight junction between itself and the cancer cell that’s structurally identical to the connection T cells normally form when they recognize a threat. The T cell then releases perforin and granzymes, two substances that work together to punch holes in the cancer cell’s membrane and trigger its self-destruction from the inside. The key advantage is that this process bypasses the cancer cell’s usual escape routes. Tumors often evade immune detection by hiding from T-cell receptors, but the bispecific antibody doesn’t care about those disguises. It forces the connection regardless.
After killing one cancer cell, the T cell detaches and can be redirected to kill another, making the process catalytic rather than one-and-done.
Approved Bispecific Antibodies
Several bispecific antibodies have reached the market, primarily for cancers that are difficult to treat with conventional therapies. Blinatumomab, the first BiTE molecule approved, targets a protein called CD19 on leukemia cells and has become a standard treatment for certain forms of acute lymphoblastic leukemia. Teclistamab (brand name Tecvayli) was approved for adults with relapsed or refractory multiple myeloma who have already tried at least one other line of treatment. In early 2026, it received an additional approval for use in combination with another antibody therapy.
Amivantamab (Rybrevant) takes a different approach entirely. Rather than engaging T cells, it simultaneously targets two growth-signaling receptors on cancer cells, blocking the pathways tumors use to grow and spread. It’s approved for certain types of non-small cell lung cancer and is now available in both intravenous and subcutaneous formulations.
The clinical pipeline has expanded rapidly. A 2024 analysis identified 681 registered clinical trials evaluating 183 distinct bispecific antibodies, a figure that doubled since 2019.
Side Effects and Cytokine Release Syndrome
The same potent immune activation that makes T-cell engaging bispecifics effective also creates their most significant side effect: cytokine release syndrome, or CRS. When T cells are activated in large numbers, they release a flood of inflammatory signaling molecules. This can cause fever, low blood pressure, difficulty breathing, and in rare cases, organ damage.
In the pivotal trial of teclistamab for multiple myeloma, CRS occurred in 72.1% of patients. That sounds alarming, but severity matters more than frequency. About half of all patients (50.3%) experienced only grade 1 CRS, meaning mild symptoms like fever. Another 21.2% had grade 2 (moderate) reactions. Only a single patient out of 165 developed grade 3 CRS, and that case involved a concurrent infection. Most CRS events happened during the initial step-up dosing period, when the drug is given in gradually increasing amounts specifically to reduce the intensity of immune activation.
CRS that recurs can be managed effectively. When doctors administered an anti-inflammatory drug at the first CRS event, only 20% of patients experienced CRS again, compared to 62.2% who had recurrence when the anti-inflammatory was withheld initially.
Why Manufacturing Is Complicated
Building a protein with two different binding arms is harder than it sounds. A standard antibody has two identical heavy chains and two identical light chains, and they naturally pair up correctly. A bispecific antibody needs two different heavy chains and potentially two different light chains, all in the same molecule. When you put all these chains into a production cell, they can mismatch in multiple ways: two identical heavy chains can pair together (homodimers), light chains can swap to the wrong heavy chain, or unusual hybrid species can form.
One widely used solution is called “knob-into-hole” engineering, where one heavy chain is modified with a bulky amino acid (the knob) and the other with a corresponding cavity (the hole), so they preferentially pair with each other rather than with themselves. Even with these modifications, unwanted mispaired species still appear at low levels and must be removed through multiple purification steps. Manufacturers use a series of specialized chromatography techniques to whittle mispaired products down to as low as 0.2% in the final drug product.
Uses Beyond Cancer
While oncology dominates the bispecific antibody landscape, the dual-targeting concept has natural applications in other diseases. One of the most successful non-cancer examples is emicizumab, a bispecific antibody approved for hemophilia A. It mimics a missing clotting factor by simultaneously binding two proteins in the blood-clotting cascade, holding them in the right orientation to restore normal clot formation. For patients who previously needed frequent injections of clotting factor, emicizumab offered a dramatic improvement in quality of life.
In autoimmune diseases, bispecific antibodies are being tested against rheumatoid arthritis, systemic lupus erythematosus, and psoriasis. The logic is appealing: many autoimmune conditions involve multiple inflammatory pathways, and blocking two at once with a single molecule could outperform drugs that target only one. Clinical results so far have been mixed. Phase II trials of one bispecific showed promise in lupus, while others targeting osteoarthritis and lung fibrosis did not meet their goals. The field is still early, but the potential to simplify treatment by replacing two separate drugs with one bispecific molecule continues to drive development.